White Paper: Enhancing Patient Access with Early Access Programs

Design and Implementation Recommendations

Publications
Category:
Published on:
December 3, 2021
Written by:
Nerea Blanqué-Catalina, Luis Culla, Marie-Aude Ohresser, and Romain Finas

Pharmaceutical companies are facing an increasing demand from physicians for Early Access Programs (EAPs) and are willing to make their innovative medicines available to patients with a high unmet medical need before their commercialization.

Pre-launch strategies aim to address public health issues and to bring significant benefits to pharmaceutical companies, patients, and physicians. Such strategies aim to respond to regulatory delays, generate more KOL engagement, and enhance future P&R negotiations.

Download this white paper “Enhancing Patient Access with Early Access Programs: Design and Implementation Recommendations” in order to:
  • understand the complexity of launching EAPs
  • discover EAPs benefits
  • learn about the related challenges and ways to overcome them

Related news

Multimedia June 21, 2022
Increasing Access to Genomic Testing in Europe
Listen to the episode “Increasing Access to Genomic Testing in Europe: The role of national genomic initiatives in increasing uptake of Advanced Diagnostics”.
Genomic Testing Market Access MedTech
Multimedia May 10, 2022
VacciTalks: Behind the Scenes: Challenging Race of Vaccine Development
Join the 2nd episode of VacciTalks where together with vaccine expert Roberto Camerini we will peek behind the scenes of vaccine development and get an insider look at the difficulties,(...)
Market Access
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
Multimedia April 28, 2022
Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe
Learn more about RWD as a support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.
Clinical Market Access RWE
Publications April 20, 2022
White Paper: Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective
In this white paper, we will explore wide range of new therapies we term “Next Generation Therapies” and challenges related to them.
Market Access
Publications March 31, 2022
Real-World Evidence: Five Facts You Need to Know
Learn more about RWD and its future challenges for Europe, we asked Romain Finas, Vice President of Real-World Evidence (RWE) at Alira Health, to share five facts that you need to know about it.
Market Access RWE
Publications March 25, 2022
Early Access Programs: Keys to Success
Discover Alira Health’s top five recommendations to building a successful Early Access Programs (EAP). 
Market Access
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.